{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:12:27Z","timestamp":1791295947819,"version":"4.1.0"},"reference-count":72,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["dmidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.diagmicrobio.2015.04.008","type":"journal-article","created":{"date-parts":[[2015,5,2]],"date-time":"2015-05-02T14:57:16Z","timestamp":1430578636000},"page":"303-313","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":112,"title":["Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values"],"prefix":"10.1016","volume":"82","author":[{"given":"M.A.","family":"Pfaller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.R.","family":"Rhomberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.A.","family":"Messer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.N.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Castanheira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0005","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1093\/cid\/cit136","article-title":"Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations","volume":"56","author":"Alexander","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0010","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1128\/JCM.01811-10","article-title":"National surveillance of fungemia in Denmark (2004 to 2009)","volume":"49","author":"Arendrup","year":"2011","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0015","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1128\/AAC.06369-11","article-title":"Differential in vivo activity of anidulafungin, caspofungin and micafungin against C. glabrata with and without FKS resistance mutations","volume":"56","author":"Arendrup","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0020","doi-asserted-by":"crossref","first-page":"E343","DOI":"10.1111\/1469-0691.12212","article-title":"Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: data from a nationwide fungaemia surveillance programme","volume":"19","author":"Arendrup","year":"2013","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0025","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1093\/cid\/ciu407","article-title":"FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia","volume":"59","author":"Beyda","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0030","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1128\/AAC.01711-09","article-title":"Low prevalence of fks1 hotspot 1 mutations in a worldwide collection of Candida spp","volume":"54","author":"Castanheira","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11046-014-9772-2","article-title":"Isavuconazole and nine comparator antifungal susceptibility profiles for common and uncommon Candida species collected in 2012: application of new CLSI clinical breakpoints and epidemiological cutoff values","volume":"178","author":"Castanheira","year":"2014","journal-title":"Mycopathologia"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0040","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1128\/AAC.01674-13","article-title":"Frequency of fks mutations among Candida glabrata isolates from a 10-year global collection of bloodstream infection isolates","volume":"58","author":"Castanheira","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0045","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ijantimicag.2014.06.007","article-title":"Activity of echinocandins and triazoles against a contemporary (2012) worldwide collection of yeast and moulds collected from invasive infections","volume":"44","author":"Castanheira","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0050","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3109\/1040841X.2010.489506","article-title":"Candida tropicalis in human disease","volume":"36","author":"Chai","year":"2010","journal-title":"Crit Rev Microbiol"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0055","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/j.1469-0691.2009.02821.x","article-title":"Candidaemia with uncommon Candida species: predisposing factors, outcome, antifungal susceptibility, and implications for management","volume":"15","author":"Chen","year":"2009","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0060","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s10156-012-0412-9","article-title":"Fatal candidemia caused by azole-resistant Candida tropicalis in patients with hematological malignancies","volume":"18","author":"Chong","year":"2012","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0065","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/cid\/cis697","article-title":"Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008\u20132011","volume":"55","author":"Cleveland","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0070","series-title":"M38-A2. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2008"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0075","series-title":"M27-A3. Reference method for broth dilution antifungal susceptibility testing of yeasts","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2008"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0080","series-title":"Reference method for broth dilution antifungal susceptibility testing of yeasts: 4th informational supplement","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2012"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0085","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.diagmicrobio.2011.08.004","article-title":"Invasive infection in an acute myeloblastic leukemia patient due to triazole-resistant Candida tropicalis","volume":"71","author":"de Carvalho Parahym","year":"2011","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0095","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1128\/JCM.00942-09","article-title":"In vitro activity of seven systemically active antifungal agents against a large global collection of rare Candida species as determined by CLSI broth microdilution methods","volume":"47","author":"Diekema","year":"2009","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0090","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.diagmicrobio.2012.02.001","article-title":"The changing epidemiology of healthcare-associated candidemia over three decades","volume":"73","author":"Diekema","year":"2012","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0100","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1128\/JCM.00536-10","article-title":"Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document)","volume":"48","author":"Espinel-Ingroff","year":"2010","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0105","doi-asserted-by":"crossref","first-page":"5898","DOI":"10.1128\/AAC.01115-12","article-title":"Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole","volume":"56","author":"Espinel-Ingroff","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0110","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1128\/AAC.06252-11","article-title":"Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for amphotericin B and flucytosine","volume":"56","author":"Espinel-Ingroff","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0115","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1128\/AAC.02615-13","article-title":"Multilaboratory study of epidemiological cutoff values for detection of resistance in eight Candida species to fluconazole, posaconazole, and voriconazole","volume":"58","author":"Espinel-Ingroff","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0120","doi-asserted-by":"crossref","first-page":"e954","DOI":"10.1016\/j.ijid.2010.04.006","article-title":"Relative frequency of albicans and the various non-albicans Candida spp among candidemia isolates from inpatients in various parts of the world: a systematic review","volume":"14","author":"Falagas","year":"2010","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0125","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1128\/AAC.00051-14","article-title":"Efficacy and tolerability of micafungin monotherapy for candidemia and deep-seated candidiasis in adults with cancer","volume":"58","author":"Farmakiotis","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0130","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1586\/eri.09.67","article-title":"New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance","volume":"7","author":"Fera","year":"2009","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0135","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ijantimicag.2014.03.010","article-title":"Combination therapy in the treatment of experimental invasive fungal infection by Sarocladium (Acremonium) kiliense","volume":"44","author":"Fernandez-Silva","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0140","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.1128\/AAC.00802-08","article-title":"Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies","volume":"52","author":"Garcia-Effron","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0145","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1086\/516098","article-title":"Acremonium species: new emerging fungal opportunists\u2014in vitro antifungal susceptibilities and review","volume":"25","author":"Guarro","year":"1997","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0150","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1128\/AAC.01512-07","article-title":"In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species","volume":"52","author":"Guinea","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0155","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1128\/AAC.00685-10","article-title":"In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens","volume":"54","author":"Guinea","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0160","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1002\/cncr.23466","article-title":"The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy","volume":"112","author":"Hachem","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0165","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.3201\/eid1507.090043","article-title":"Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure","volume":"15","author":"Howard","year":"2009","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0170","series-title":"Manual of clinical microbiology","first-page":"1793","article-title":"Candida, Cryptococcus, and other yeasts of medical importance","author":"Howell","year":"2011"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0175","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1128\/AAC.01193-12","article-title":"Stepwise development of a homozygous S80P substitution in Fks1p, conferring echinocandin resistance in Candida tropicalis","volume":"57","author":"Jensen","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0180","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1128\/JCM.02278-10","article-title":"Acremonium kiliense: reappraisal of its clinical significance","volume":"49","author":"Khan","year":"2011","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0185","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.amjmed.2011.10.009","article-title":"Invasive mycoses: strategies for effective management","volume":"125","author":"Kontoyiannis","year":"2012","journal-title":"Am J Med"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0190","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1099\/jmm.0.013227-0","article-title":"Candida tropicalis: its prevalence, pathogenicity and increasing resistance to fluconazole","volume":"59","author":"Kothavade","year":"2010","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0195","series-title":"Medically important fungi: a guide to identification","author":"Larone","year":"2002"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0200","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1093\/cid\/ciu319","article-title":"The Antimicrobial Resistance Monitoring and Research (ARMoR) Program: The US Department of Defense Response to Escalating Antimicrobial Resistance","volume":"59","author":"Lesho","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0205","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.diagmicrobio.2014.02.016","article-title":"Candidemia surveillance in Iowa: emergence of echinocandin resistance","volume":"79","author":"Matsumoto","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0215","doi-asserted-by":"crossref","first-page":"e666","DOI":"10.1111\/j.1439-0507.2011.02032.x","article-title":"Emerging moulds: epidemiological trends and antifungal resistance","volume":"54","author":"Miceli","year":"2011","journal-title":"Mycoses"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0210","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S1473-3099(10)70218-8","article-title":"Emerging opportunistic yeast infections","volume":"11","author":"Miceli","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0220","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3109\/13693786.2012.708107","article-title":"Is the incidence of candidemia caused by Candida glabrata increasing in Brazil? Five-year surveillance of Candida bloodstream infection in a university reference hospital in southeast Brazil","volume":"51","author":"Moretti","year":"2013","journal-title":"Med Mycol"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0225","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/cid\/cit140","article-title":"Candida glabrata and FKS mutations: witnessing the emergence of the true multidrug-resistant Candida","volume":"56","author":"Ostrosky-Zeichner","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0230","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/jac\/dkm453","article-title":"Emergence of Candida tropicalis resistant to caspofungin","volume":"61","author":"Pasquale","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0235","doi-asserted-by":"crossref","first-page":"4419","DOI":"10.1128\/JCM.42.10.4419-4431.2004","article-title":"Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus","volume":"42","author":"Pfaller","year":"2004","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0275","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1128\/JCM.00937-12","article-title":"Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012","volume":"50","author":"Pfaller","year":"2012","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0240","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1128\/JCM.00865-06","article-title":"Candida guilliermondii, an opportunistic fungal pathogen with decreased susceptibility to fluconazole: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program","volume":"44","author":"Pfaller","year":"2006","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0245","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1128\/JCM.01155-09","article-title":"In vitro susceptibility of clinical isolates of Aspergillus spp. to anidulafungin, caspofungin, and micafungin: a head-to-head comparison using the CLSI M38-A2 broth microdilution method","volume":"47","author":"Pfaller","year":"2009","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0250","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1128\/JCM.00946-09","article-title":"Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location in the United States in 2001 to 2007","volume":"47","author":"Pfaller","year":"2009","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0255","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.diagmicrobio.2010.01.002","article-title":"Geographic variation in the frequency of isolation and fluconazole and voriconazole susceptibilities of Candida glabrata: an assessment from the ARTEMIS DISK Global Antifungal Surveillance Program","volume":"67","author":"Pfaller","year":"2010","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0260","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.diagmicrobio.2011.03.002","article-title":"Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria","volume":"70","author":"Pfaller","year":"2011","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0265","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1128\/JCM.06112-11","article-title":"Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata","volume":"50","author":"Pfaller","year":"2012","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0270","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s11046-012-9551-x","article-title":"Significance of molecular identification and antifungal susceptibility of clinically significant yeasts and moulds in a global antifungal surveillance programme","volume":"174","author":"Pfaller","year":"2012","journal-title":"Mycopathologia"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0280","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1128\/JCM.00863-13","article-title":"In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds","volume":"51","author":"Pfaller","year":"2013","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0285","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1128\/JCM.00308-13","volume":"51","author":"Pfaller","year":"2013","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0290","doi-asserted-by":"crossref","first-page":"e101510","DOI":"10.1371\/journal.pone.0101510","article-title":"Epidemiology and outcomes of invasive candidiasis due to non-albicans species of Candida in 2,496 patients: data from the Prospective Antifungal Therapy (PATH) registry 2004\u20132008","volume":"9","author":"Pfaller","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0295","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/myc.12206","article-title":"Regional data analysis of Candida non-albicans strains collected in United States medical sites over a 6-year period, 2006\u20132011","volume":"57","author":"Pfaller","year":"2014","journal-title":"Mycoses"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0300","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1128\/AAC.02020-13","article-title":"Multicenter study of anidulafungin and micafungin MIC distributions and epidemiological cutoff values for eight Candida species and the CLSI M27-A3 broth microdilution method","volume":"58","author":"Pfaller","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0305","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1128\/AAC.03255-14","article-title":"The role of FKS mutations in C. glabrata: MIC values, echinocandin resistance and multidrug resistance","volume":"58","author":"Pham","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0310","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1128\/AAC.00156-08","article-title":"Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus","volume":"52","author":"Rodriguez-Tudela","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0315","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1469-0691.2007.01892.x","article-title":"Candida glabrata fungaemia in intensive care units","volume":"14","author":"Ruan","year":"2008","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0320","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ijantimicag.2009.02.021","article-title":"Candida glabrata fungaemia in a tertiary centre in Taiwan: antifungal susceptibility and outcomes","volume":"34","author":"Ruan","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0325","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1099\/jmm.0.045054-0","article-title":"Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options","volume":"62","author":"Sardi","year":"2013","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0330","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1439-0507.2010.01960.x","article-title":"What do we know about Candida guilliermondii? A voyage throughout past and current literature about this emerging yeast","volume":"54","author":"Savini","year":"2011","journal-title":"Mycoses"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0335","doi-asserted-by":"crossref","first-page":"4862","DOI":"10.1128\/AAC.00027-12","article-title":"The presence of an FKS mutation rather than minimum inhibitory concentration is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata","volume":"56","author":"Shields","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0340","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1002\/cncr.24507","article-title":"Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001\u20132007): stable incidence but changing epidemiology of a still frequently lethal infection","volume":"115","author":"Sipsas","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0350","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s11046-010-9324-3","article-title":"Isavuconazole: a comprehensive review of spectrum of activity of a new triazole","volume":"170","author":"Thompson","year":"2010","journal-title":"Mycopathologia"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0345","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/jac\/dkp138","article-title":"In vitro activity of isavuconazole against Trichosporon, Rhodotorula, Geotrichum, Saccharomyces and Pichia species","volume":"64","author":"Thompson","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0355","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1086\/502294","article-title":"Susceptibilities of Candida species to amphotericin B and fluconazole: the emergence of fluconazole resistance in Candida tropicalis","volume":"25","author":"Yang","year":"2004","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.diagmicrobio.2015.04.008_bb0360","doi-asserted-by":"crossref","first-page":"5042","DOI":"10.1128\/AAC.00836-10","article-title":"FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from U.S. population-based surveillance","volume":"54","author":"Zimbeck","year":"2010","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889315001303?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889315001303?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,22]],"date-time":"2018-09-22T20:23:39Z","timestamp":1537647819000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889315001303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":72,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S0732889315001303"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2015.04.008","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2015.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}